Insider Selling: Revolution Medicines (NASDAQ:RVMD) COO Sells 4,775 Shares of Stock

Key Points

• Revolution Medicines' COO Margaret Horn sold 4,775 shares of stock at an average price of $45.82, decreasing her ownership in the company by 3.17%.
• The company's shares recently traded at $45.28 with a market capitalization of $8.46 billion and a debt-to-equity ratio of 0.13.
• Analysts have generally rated Revolution Medicines as a "Buy," with an average price target of $73.67 and recent upgrades from firms such as Wedbush and Wells Fargo.

Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) COO Margaret A. Horn sold 4,775 shares of the firm's stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $45.82, for a total value of $218,790.50. Following the transaction, the chief operating officer directly owned 145,900 shares in the company, valued at $6,685,138. This trade represents a 3.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Revolution Medicines Trading Up 2.0%

Shares of NASDAQ:RVMD traded up $0.87 on Monday, reaching $44.41. 1,768,629 shares of the company traded hands, compared to its average volume of 2,155,438. The business's 50-day simple moving average is $38.65 and its 200 day simple moving average is $38.36. Revolution Medicines, Inc. has a 52 week low of $29.17 and a 52 week high of $62.40. The company has a quick ratio of 11.79, a current ratio of 11.79 and a debt-to-equity ratio of 0.13.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.37). During the same quarter in the previous year, the company earned ($0.81) earnings per share. Revolution Medicines's revenue for the quarter was up .0% compared to the same quarter last year. Analysts expect that Revolution Medicines, Inc. will post -3.49 earnings per share for the current year.

Analysts Set New Price Targets

RVMD has been the topic of several recent analyst reports. Piper Sandler assumed coverage on Revolution Medicines in a research note on Monday, August 18th. They issued an "overweight" rating and a $75.00 target price on the stock. Wedbush boosted their price objective on shares of Revolution Medicines from $73.00 to $77.00 and gave the stock an "outperform" rating in a report on Thursday, September 11th. Truist Financial began coverage on shares of Revolution Medicines in a report on Friday, September 5th. They issued a "buy" rating and a $99.00 price objective for the company. The Goldman Sachs Group boosted their target price on shares of Revolution Medicines from $65.00 to $73.00 and gave the company a "buy" rating in a research note on Friday, September 12th. Finally, Lifesci Capital started coverage on shares of Revolution Medicines in a research note on Monday, August 18th. They set an "outperform" rating and a $80.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating and fourteen have assigned a Buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $73.67.

Institutional Trading of Revolution Medicines

Several hedge funds have recently bought and sold shares of the stock. Wellington Management Group LLP lifted its stake in Revolution Medicines by 8.9% in the 1st quarter. Wellington Management Group LLP now owns 11,787,921 shares of the company's stock worth $416,821,000 after purchasing an additional 966,230 shares in the last quarter. Nextech Invest Ltd. lifted its stake in Revolution Medicines by 20.7% in the 4th quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company's stock worth $332,472,000 after purchasing an additional 1,304,347 shares in the last quarter. BVF Inc. IL lifted its stake in Revolution Medicines by 19.2% in the 1st quarter. BVF Inc. IL now owns 4,982,384 shares of the company's stock worth $176,177,000 after purchasing an additional 801,205 shares in the last quarter. Bellevue Group AG lifted its stake in Revolution Medicines by 4.7% in the 2nd quarter. Bellevue Group AG now owns 4,579,300 shares of the company's stock worth $168,472,000 after purchasing an additional 205,000 shares in the last quarter. Finally, Lunate Capital Ltd purchased a new stake in Revolution Medicines in the 1st quarter worth $77,658,000. Hedge funds and other institutional investors own 94.34% of the company's stock.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.